RNF43 and colorectal carcinoma: In summary, the presence of RNF43 mutations in CRCs and the effectiveness of PORCN inhibitors on a number of RNF43-mediated CRC models provide optimism and opportunity to develop therapeutics targeting Wnt signaling.